Literature DB >> 17154249

Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours.

L Khalique1, A Ayhan, M E Weale, I J Jacobs, S J Ramus, S A Gayther.   

Abstract

Genetic analysis of solid tumours using DNA or cDNA expression microarrays may enable individualized treatment based on the profiles of genetic changes that are identified from each patient. This could result in better response to adjuvant chemotherapy and, consequently, improved clinical outcome. So far, most research studies that have tested the efficacy of such an approach have sampled only single areas of neoplastic tissue from tumours; this assumes that the genetic profile within solid tumours is homogeneous throughout. The aim of this study was to evaluate the extent of genetic intra-tumour heterogeneity (ITH) within a series of epithelial ovarian cancers. Several different regions (five to eight regions) of tumour tissue from 16 grade 3, serous epithelial ovarian cancers were analysed for genetic alterations using a combination of microsatellite analysis and single nucleotide polymorphism (SNP) analysis, in order to establish the extent of ITH. Maximum parsimony tree analysis was applied to the genetic data from each tumour to evaluate the clonal relationship between different regions within tumours. Extensive ITH was identified within all ovarian cancers using both microsatellite and SNP analysis. Evolutionary analysis of microsatellite data suggested that the origin of all tumours was monoclonal, but that subsequent clonal divergence created mixed populations of genetically distinct cells within the tumour. SNP analysis suggested that ITH was not restricted to random genetic changes, but affected genes that have an important functional role in ovarian cancer development. The frequent occurrence of ITH within epithelial ovarian cancers may have implications for the interpretation of genetic data generated from emerging technologies such as DNA and mRNA expression microarrays, and their use in the clinical management of patients with ovarian cancer. The basis of genetic ITH and the possible implications for molecular approaches to clinical diagnosis of ovarian cancers may apply to other tumour types. Copyright 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2007        PMID: 17154249     DOI: 10.1002/path.2112

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  48 in total

1.  Tracing the tumor lineage.

Authors:  Nicholas E Navin; James Hicks
Journal:  Mol Oncol       Date:  2010-05-05       Impact factor: 6.603

2.  Empirical chemosensitivity testing in a spheroid model of ovarian cancer using a microfluidics-based multiplex platform.

Authors:  Tamal Das; Liliane Meunier; Laurent Barbe; Diane Provencher; Olivier Guenat; Thomas Gervais; Anne-Marie Mes-Masson
Journal:  Biomicrofluidics       Date:  2013-01-10       Impact factor: 2.800

3.  Genetic analysis of uterine aspirates improves the diagnostic value and captures the intra-tumor heterogeneity of endometrial cancers.

Authors:  Alba Mota; Eva Colás; Pablo García-Sanz; Irene Campoy; Alejandro Rojo-Sebastián; Sonia Gatius; Ángel García; Luis Chiva; Sonsoles Alonso; Antonio Gil-Moreno; Xavier González-Tallada; Berta Díaz-Feijoo; August Vidal; Patrycja Ziober-Malinowska; Marcin Bobiński; Rafael López-López; Miguel Abal; Jaume Reventós; Xavier Matias-Guiu; Gema Moreno-Bueno
Journal:  Mod Pathol       Date:  2016-09-02       Impact factor: 7.842

Review 4.  Evolution of the cancer genome.

Authors:  Ondrej Podlaha; Markus Riester; Subhajyoti De; Franziska Michor
Journal:  Trends Genet       Date:  2012-02-16       Impact factor: 11.639

5.  A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome.

Authors:  Hebert Alberto Vargas; Harini Veeraraghavan; Maura Micco; Stephanie Nougaret; Yulia Lakhman; Andreas A Meier; Ramon Sosa; Robert A Soslow; Douglas A Levine; Britta Weigelt; Carol Aghajanian; Hedvig Hricak; Joseph Deasy; Alexandra Snyder; Evis Sala
Journal:  Eur Radiol       Date:  2017-03-13       Impact factor: 5.315

6.  Network analysis identifies an HSP90-central hub susceptible in ovarian cancer.

Authors:  Hanqing Liu; Fang Xiao; Ilya G Serebriiskii; Shane W O'Brien; Marisa A Maglaty; Igor Astsaturov; Samuel Litwin; Lainie P Martin; David A Proia; Erica A Golemis; Denise C Connolly
Journal:  Clin Cancer Res       Date:  2013-07-30       Impact factor: 12.531

7.  Association between morphologic CT imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: a hypothesis-generating study.

Authors:  Hebert Alberto Vargas; Maura Miccò; Seong Im Hong; Debra A Goldman; Fanny Dao; Britta Weigelt; Robert A Soslow; Hedvig Hricak; Douglas A Levine; Evis Sala
Journal:  Radiology       Date:  2014-11-10       Impact factor: 11.105

8.  Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance.

Authors:  Robert M W Hofstra; Amanda B Spurdle; Diana Eccles; William D Foulkes; Niels de Wind; Nicoline Hoogerbrugge; Frans B L Hogervorst
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

9.  Inferring tumor progression from genomic heterogeneity.

Authors:  Nicholas Navin; Alexander Krasnitz; Linda Rodgers; Kerry Cook; Jennifer Meth; Jude Kendall; Michael Riggs; Yvonne Eberling; Jennifer Troge; Vladimir Grubor; Dan Levy; Pär Lundin; Susanne Månér; Anders Zetterberg; James Hicks; Michael Wigler
Journal:  Genome Res       Date:  2009-11-10       Impact factor: 9.043

10.  Sampling strategies for tissue microarrays to evaluate biomarkers in ovarian cancer.

Authors:  Jenny Permuth-Wey; David Boulware; Nikola Valkov; Sandra Livingston; Santo Nicosia; Ji-Hyun Lee; Rebecca Sutphen; Joellen Schildkraut; Steven Narod; Alex Parker; Domenico Coppola; Thomas Sellers; Tuya Pal
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.